摘要
抗逆转录病毒药物引起肝毒性比较常见，而且每类药物肝毒性机制不同。儿童患者HAART相关肝毒性的发生机制与成人患者相似，但发生率要低一些。HAART开始后的早期阶段要加强对肝毒性的监测，及时发现肝功能异常，如果肝酶升高超过10倍正常上限或出现肝炎症状要及时停药，如果肝毒性是由奈韦拉平或阿巴卡韦引起的，停药后不要再次应用，以防致命反应的发生。
HAART-related hepatoxicity is common and the mechanisms vary in different class of antiretrovirals. The mechanisms are similar in children and adults, but hepatoxicity is less frequent in children. Close monitoring is needed, especially at the early stage of HAART. Discontinuation of HAART is necessary when liver enzymes are elevated to greater than 10-fold upper limit of normal or symptomatic hepatitis development. Nevirapine or abacavir should not be rechallenged after discontinuation due to hepatoxicity.
出处
《国际流行病学传染病学杂志》
CAS
2008年第4期252-254,共3页
International Journal of Epidemiology and Infectious Disease
基金
北京市科委重大科研项目（D09136003040591）
